466 related articles for article (PubMed ID: 21362516)
1. Metabolic positron emission tomography imaging in cancer detection and therapy response.
Zhu A; Lee D; Shim H
Semin Oncol; 2011 Feb; 38(1):55-69. PubMed ID: 21362516
[TBL] [Abstract][Full Text] [Related]
2. Application of metabolic PET imaging in radiation oncology.
Zhu A; Marcus DM; Shu HK; Shim H
Radiat Res; 2012 Apr; 177(4):436-48. PubMed ID: 22339451
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
Powles T; Murray I; Brock C; Oliver T; Avril N
Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
[TBL] [Abstract][Full Text] [Related]
5. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of positron emission tomography in sarcoma management.
Quak E; van de Luijtgaarden AC; de Geus-Oei LF; van der Graaf WT; Oyen WJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):195-204. PubMed ID: 21342039
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
8. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
9. Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.
Smyth EC; Shah MA
World J Gastroenterol; 2011 Dec; 17(46):5059-74. PubMed ID: 22171140
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
12. [The use of 18F-fluorothymidine and 18F-fluorocholine in imaging with positron emission tomography].
Skoura E; Datseris IE
Hell J Nucl Med; 2010; 13(1):88-90. PubMed ID: 20411184
[TBL] [Abstract][Full Text] [Related]
13. Clinical role of FDG PET in evaluation of cancer patients.
Kostakoglu L; Agress H; Goldsmith SJ
Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
[TBL] [Abstract][Full Text] [Related]
14. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.
Yanagawa T; Watanabe H; Inoue T; Ahmed AR; Tomiyoshi K; Shinozaki T; Oriuchi N; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(2):175-82. PubMed ID: 12703009
[TBL] [Abstract][Full Text] [Related]
15. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
16. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
Kubota K
Ann Nucl Med; 2001 Dec; 15(6):471-86. PubMed ID: 11831394
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT imaging in oncology.
Almuhaideb A; Papathanasiou N; Bomanji J
Ann Saudi Med; 2011; 31(1):3-13. PubMed ID: 21245592
[TBL] [Abstract][Full Text] [Related]
18. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology.
Fukuda H; Kubota K; Matsuzawa T
Tohoku J Exp Med; 2013 Jul; 230(3):155-69. PubMed ID: 23883588
[TBL] [Abstract][Full Text] [Related]
19. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
[TBL] [Abstract][Full Text] [Related]
20. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
Lin CY; Lin CL; Kao CH
Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]